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Defluorination of 4-fluorothreonine by threonine
deaminase†
Linrui Wu and Hai Deng *
4-Fluorothreonine (4-FT) is the only naturally occurring fluorinated
amino acid antibiotic. Although two conserved proteins in the
4-FT pathway have been found to be involved in self-detoxification
mechanisms, the 4-FT-producing strains may also require an
alternative pathway to degrade the intracellular 4-FT. In this study,
we examined the possible degradation role of three enzymes
involved in threonine metabolite pathways toward 4-FT as a poss-
ible degradation route to avoid in vivo 4-FT accumulation. Among
these three enzymes, threonine deaminase was found to catalyse a
defluorination reaction to generate 4-hydroxy-α-ketobutyrate,
which is supposed to be further metabolised by an aldolase that
likely is a unique occurrence in the 4-FT-producing strains. Our
finding may constitute a 4-FT degradation pathway as a comp-
lementary resistance mechanism.
Introduction
For decades, bacteria have been known as the most prolifera-
tive producers of natural products (NPs), which account for
over 40% of lead small molecules in drug discovery.1 In most
cases, in bacteria, genes responsible for their synthesis are
clustered together to form biosynthetic gene clusters (BGCs),
enabling a more efficient expression regulation and functional
assembly.2 To guard the host strain from the generated NPs, it
is a common strategy for BGCs to incorporate a resistance
gene, conferring a detoxification mechanism for self-protec-
tion.3 This knowledge in turn has facilitated the genome
mining process for new NP discovery.4
Despite the similarities of the steric properties between fluo-
rine and hydrogen atoms, fluorinated drug molecules are often
endowed with advantages compared to their non-fluorinated
counterparts, such as a low susceptibility towards oxidative
metabolism by cytochrome P450 monooxygenases and degrad-
ing hydrolytic effects.5 In contrast to the widely distributed syn-
thetic fluorinated compounds, naturally occurring fluorometa-
bolites are rare. However, their occurrence has attracted new
research interest from the blooming fluorinated drug discovery
industry using fluorine biocatalysts under mild conditions for
stereo- and regio-selective fluorination.6 The most well-studied
fluorometabolites, the toxin fluoroacetate (FAc) 1 and the anti-
biotic 4-fluorothreonine (4-FT) 2, were first identified in
Streptomyces cattleya.7 The biosynthetic pathways of these two
fluorometabolites have been well studied with the hallmark
studies of the first naturally occurring fluorination enzyme,
fluorinase, the first committed enzyme in fluorometabolism.8–11
Later on, genome mining revealed several other putative fluoro-
metabolite-producing strains including Nocardia brasiliensis,
Actinoplanes sp. N902-109, and the marine-derived Streptomyces
xinghaiensis.12,13 In 2012, we identified the prolific fluorometa-
bolite-producing strain Streptomyces sp. MA37 in Ghana, Africa
that also produces a wide range of fluorinated NPs, including
5-fluoro-2,3,4-trihydroxypentanoic acid (FHPA) 3 (Fig. 1A).12,14
Unlike most of the microbial natural products, many of the
genes responsible for bacterial fluorometabolites are spread in
the genomes of the corresponding fluorometabolite-producing
strains.15 Enzymes from primary metabolism, such as 5-methyl-
thio-5-deoxy-ribose isomerase, may also act on the intermedi-
ates in the fluorometabolite pathway, due to the structural simi-
larity among the fluorinated intermediates and intermediates
from primary metabolism.10
Due to the similar steric properties between fluorine and
hydrogen, both FAc 1 and 4-FT 2 can enter various primary
metabolite pathways related to acetate and L-Thr, respectively.
These misincorporations can be disruptive and toxic to the
producing strains, which in turn have evolved to counteract
with potential detoxification strategies.16 The resistance
mechanism of host strains towards FAc 1 has been character-
ized. The toxicity of 1 arises from the transformation of 1, via
fluoroacetyl-CoA, to the potent toxin (2R,3R)-fluorocitrate,
which is a potent inhibitor of aconitase, a key enzyme of the
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citric acid cycle. In the case of 1 in the producing strains, a
specialised fluoroacetyl-CoA thioesterase, FlK, can selectively
hydrolyse the misacylated fluoroacetyl-CoA to prevent the acti-
vation of fluoroacetate (Fig. 1B).17–19 The detoxification
mechanism of 4-FT 2 employed by S. cattleya has also been
extensively elaborated by the study of FthB and FthC, the
fluorothreonyl-tRNA deacylase and 4-FT transporter, respect-
ively. The structural similarity between 4-FT 2 and L-Thr
allows 2 to form a misacylated tRNA, 4-FT-tRNA, hence enter-
ing the ribosomal protein biosynthesis. FthB, the fluorothreo-
nyl-tRNA deacylase, can hydrolyse the 4-FT misacylated tRNA
and reduce the misincorporation of 4-FT (Fig. 1B).20
Interestingly, the genetic knock-out studies on both
S. cattleya and S. MA37 showed that its inactivation does not
result in the fluctuation of fluorometabolite biosynthesis or
the strain’s phenotype alteration.21 The inactivation of the
4-FT transporter FthC, which led to increased intracellular
4-FT 2 accumulation, also does not interfere with cell
growth,20 leaving an unanswered question of the metabolic
fate of these intracellular 4-FT 2.
In different organisms, there exist various enzymes in
primary metabolism taking up L-Thr as a substrate for its
transformation (Fig. 1C). Considering the structural similarity
of 4-FT and L-Thr, these primary enzymes might also be used
for the degradation of intracellular 4-FT 2, counteracting its
poisonous effect towards the host strain.
Here we report the biochemical defluorination reaction of
4-FT 2, catalysed by threonine deaminase (TDA), which may
serve an alternative pathway of 4-FT 2 to prevent its intracellular
accumulation. The products, resulting from this defluorination
reaction, were determined to be inorganic fluoride and
4-hydroxy-α-ketobutyrate through 19F-NMR analysis, chemical
derivatization and high-resolution mass spectroscopic analysis,
and the latter product was proposed to be further degraded into
pyruvate by the promiscuous enzyme 2-keto-4-hydroxyglutarate
aldolase through comparative genomic analysis.
Results and discussion
Three enzymes that can metabolise L-Thr, threonine dehydrogen-
ase (TDH), L-amino acid oxidase (LAAO) and threonine deami-
nase (TDA), were chosen to be tested on 4-FT 2. LAAO (Sigma-
Aldrich product no. A9253), mostly found in snake venom, cata-
lyses the deamination of L-amino acids to generate the corres-
ponding α-keto acid, ammonia and hydrogen peroxide22. LAAO
has relatively broad substrate tolerance towards different amino
acids and was found to transform L-Thr to pyruvate (Fig. 1C),
albeit with less efficiency compared to amino acids with hydro-
phobic side chains.23 In our previous studies, we successfully
overexpressed the 4-fluorothreonine transaldolase FTaseMA from
Streptomyces sp. MA37 and characterized its function in the last
step of the transaldol reaction of 4-FT biosynthesis. It utilizes
L-Thr and fluoroacetaldehyde (FAd) as substrates and pyridoxal
phosphate (PLP) as a cofactor to generate 4-FT.24 To test whether
LAAO acts on 4-FT 2, we performed a coupling reaction. An assay
of LAAO with FTaseMA using L-Thr and fluoroacetaldehyde (FAd)
to generate 4-FT 2 in situ was carried out (Fig. S1†). The reaction
was monitored by 19F-NMR analysis. However, there was no
apparent new organofluorine signal appearing in the 19F-NMR
spectrum while 4-FT 2 from the FTaseMA biochemical reaction
accumulated, suggesting that the fluorine atom at the C4 posi-
tion of 4-FT 2 strongly inhibits the reactivity of LAAO.
Next, we overexpressed the genes, those that encode TDH
and TDA from E. coli, in E. coli BL21(DE3) and purified them
to near homogeneity (Fig. S2A and S3A†). TDH is responsible
for catalysing the oxidation of L-Thr to L-2-amino-3-oxobutano-
ate 4 in amino acid metabolism25 while TDA catalyses the
initial step from L-Thr to α-ketobutyrate 5 (Fig. 1C). TDA is a
crucial enzyme leading to the branched pathway of amino acid
degradation and L-isoleucine biosynthesis26 (Fig. 1C). The cata-
lytic activities of the recombinant proteins have been con-
firmed (Fig. S2B and S3B†). To examine the catalytic capacity
of TDH towards 4-FT 2, an assay of TDH coupled with
FTaseMA was performed overnight, and the reaction mixture
was analysed by 19F-NMR. No new organofluorine signals were
observed, demonstrating that 4-FT is not the substrate of TDH
(Fig. S4†). We then carried out the coupling assay of TDA with
FTaseMA and monitored the biotransformation by 19F-NMR.
Interestingly, the level of 4-FT 2 in this coupling reaction was
reduced compared to the control reaction in which TDA was
inactivated (Fig. S5†). However, no new organofluorine signals
Fig. 1 (A) The three fluorometabolites produced by MA37. (B) The
detoxification of 4-FT and FAc in S. cattleya. (C) The enzymatic reactions
on L-Thr in varisous organisms.
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were observed in the 19F-NMR spectrum, indicating that no
organofluorines were produced. Instead, we found a fluorine
signal at −121.35 ppm, corresponding to the fluoride ion. To
further demonstrate the defluorination reaction by TDA, we
developed a two-step biotransformation in a time-course
fashion. 4-FT 2 was first synthesised by FTaseMA with PLP and
L-Thr, followed by removing FTaseMA by heat denaturing.
After the depletion of FTaseMA, TDA was supplemented to the
system. As shown in Fig. 2A, 4-FT 2 was constantly consumed
as observed throughout the time scale, and the decrease of
4-FT 2 was only accompanied by the emergence of the in-
organic fluoride ion in the 19F-NMR spectrum (Fig. 2B).
To examine what products were generated during the
defluorination catalysed by TDA, we applied the derivatization
analytical method that we used in our previous study.24 2,4-
Dinitrophenylhydrazine (DNPH) was used as a derivatization
agent for monitoring aldehyde and ketone species in the reac-
tion mixture. The reaction mixture was derivatized by DNPH,
followed by HPLC analysis of keto-DNPH derivatives.27 The
derivatized mixtures were also subjected to LC-high-resolution
MS (HR-MS) analysis. In the coupling assay (Fig. 3A), three
expected DNPH-derived compounds containing keto func-
tional groups, such as α-ketobutyrate 5 (Fig. S6A†), fluoroace-
taldehyde (FAd) 7 (Fig. S6B†), and acetaldehyde (Ad) 7
(Fig. S6C†), were observed. FAd 6 and Ad 7 are the unreacted
components from the FTaseMA biotransformation system,
while α-ketobutyrate 5 is the product of TDA which acts on the
residue of L-Thr from the FTaseMA biotransformation system.
Interestingly, we also observed the presence of a new peak at a
retention time (RT) of 9.8 min. HR-MS analysis indicated that
an ion with an m/z value of 299.0629 (calcd m/z = 299.0622;
calcd MF = C10H11O7N4
+, Δ = 0.675 ppm) corresponds to this
DNPH-derived compound 8. In the control experiments where
either a combination of both denatured FTaseMA and TDA
(Fig. 3B and C) or a combination of active FTaseMA and
denatured TDA was used in the presence of substrates and co-
factors, this new peak was absent, demonstrating that 9 is gen-
erated by the coupling reaction in which both FTaseMA and
TDA were active. As a result, it is likely that TDA catalyses a
defluorination reaction on 4-FT 2 to yield the inorganic fluor-
ide ion and 2-keto-4-hydroxybutyric acid 8.
Taken together, a catalytic mechanism of the defluorination
on 4-FT, catalysed by TDA based on the current knowledge of
PLP-dependent biochemistry, is shown in Fig. 4. Both L-Thr and
4-FT 2 undergo the same pathway of β-dehydration mediated by
TDA to generate the key intermediate 9. In the case of L-Thr,
Fig. 2 The time course of the coupling reaction of FTaseMA and TDA,
showing the generation of the fluoride ion (A) and the consumption of
4-FT 2 (B). FAd 1 and 4-FT 2 were the substrate and the product left in
the FTaseMA biotransformation reaction, respectively.
Fig. 3 HPLC analysis of the reaction mixture after DNPH derivatization,
showing the production of a new compound (A) that corresponds to 2-
keto-4-hydroxybutyric acid 8, using the inactivated TDA (B), and the
inactivated FTaseMA/TDA (C) as the controls. The identity of DNPH-8
was confirmed by HRMS analysis (the blowup).
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hydrolysis of 9 would yield the imine molecule 10 which is
further hydrolysed into α-keto-butyrate 5 (Fig. 4, blue curly arrow).
In the case of 4-FT 2, it is likely that the hydrolysis, however,
would result in using the fluoride ion as the leaving group to
produce 2-iminobut-3-enoic acid 11. Subsequent Michael addition
by water results in 2-keto-4-hydroxybutyric acid 8.
The observed defluorination catalysed by TDA is consider-
ably interesting as it unusually cleaves the C–F bond, the stron-
gest covalent bond in organic chemistry. Very few enzymes dis-
covered thus far have such capacity, one of which is fluoroace-
tate dehalogenases from Burkholderia sp. and Delftia
acidovorans.28,29 These enzymes recruit Asp in their active sites
to displace the fluoride ion in an SN2 manner to generate an
enzyme-glycolate ester intermediate, followed by subsequent
hydrolysis of this ester by water to yield glycolate and recover
the enzymes to their original states.30
The identified defluorination reaction of 4-FT 2 suggested
that the host strain may recruit TDA from the primary metab-
olism for the intracellular 4-FT degeneration, preventing a toxic
level of 4-FT 2 accumulation in vivo. The examination of the
metabolic fate of 2-keto-4-hydroxybutyric acid 8 revealed that,
although not present as a common primary metabolite, it can
be accepted by the promiscuous 2-keto-4-hydroxyglutarate aldo-
lase to be converted into formaldehyde and pyruvate as pre-
sented by previous studies.31 A copy of gene-encoded 2-keto-4-
hydroxyglutarate aldolase was found in the genome of
S. cattleya (accession no. AEW93759). BLAST search using its
sequence as a query against the annotated MA37 draft genome
in the RAST server revealed the presence of one gene encoding
2-keto-4-hydroxyglutarate aldolase in MA37. Interestingly,
2-keto-4-hydroxyglutarate aldolase is rarely found in
Streptomyces including Nocardia brasiliensis and Actinoplanes
sp. N902-109 that contain fluorinases.12,32 Only twelve homolo-
gous genes were found among thousands of Streptomyces
genomes in the NCBI database. It is worth noting that Nocardia
brasiliensis cannot produce any fluorometabolites under the
laboratory conditions,12,32 and Actinoplanes sp N902-109 is not
available in the public domain so that whether this strain has
the capacity to produce fluorometabolites has not been
assessed.12 Streptomyces xinghaiensis, on the other hand, is the
fluorometabolite-producing strain that originated from marine
environments which only produces FAc 1. Bioinformatics ana-
lysis of the fluorometabolite biosynthetic gene cluster in
S. xinghaiensis suggested that the putative FTase gene is trun-
cated, meaning that the strain has no capacity for producing
4-FT 2.16 Coincidently, S. xinghaiensis lacks the 2-keto-4-hydro-
xyglutarate aldolase gene in its genome as well. Taken together,
TDA and 2-keto-4-hydroxyglutarate aldolase may constitute a
4-FT degradation pathway in the producing strains to recycle
formaldehyde and pyruvate in primary metabolism. It may
serve as a complementary mechanism in addition to FthB to
maintain a minimal level of intracellular 4-FT 2 for a normal
state of ribosomal protein biosynthesis. The potential 4-FT
degradation pathway of 4-FT catalysed by putative TDA and
2-keto-4-hydroxyglutarate aldolase from the 2 producing strains
will be the focus of our future studies.
Conclusions
In this study, we tested several L-Thr metabolism related
enzymes and conducted biochemical assays to determine their
activity against 4-FT 2. Incubation of 4-FT 2 generated by
FTaseMA with the recombinant TDA leads to the identification
of an interesting 4-FT defluorination mechanism. Bioinformatics
analysis found a copy of the 2-keto-4-hydroxyglutarate aldolase
gene in both genomes of S. cattleya and S. MA37, indicating that
there exists a new 4-FT degradation pathway for its detoxification
and recycling. Combined with the fluorothreonyl-tRNA deacy-
lase, they may serve as the 4-FT resistance mechanism employed
by the fluorometabolite-producing strains to avoid homeostasis
disruption. This discovery would also facilitate our understand-
ing of the biochemistry of fluorometabolites.
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Fig. 4 The proposed defluorination mechanism of 4-FT, catalysed by
TDA based on the current knowledge of PLP-dependent biochemistry.
The release from PLP can branch in two ways depending on the
substitution.
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